Octanine (Human Coagulation Factor Ix)

Human Coagulation Factor IX, the active ingredient in Octanine, is a coagulation factor replacement therapy presented as a sterile injectable solution for intravenous use. It replaces deficient factor IX to manage bleeding in patients with hemophilia B. GNH USA supplies Octanine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Octanine is used in the management of hemophilia B and related bleeding disorders. - Hemophilia B: provides factor IX replacement to control and prevent bleeding episodes. - Surgical procedures in hemophilia B patients: ensures adequate hemostasis during and after surgery. - Prophylactic therapy for hemophilia B: reduces the frequency of spontaneous bleeds and improves quality of life.

Octanine may be associated with several adverse reactions following infusion.

Common Side Effects: - Infusion site reactions: redness, swelling, or pain at the injection site. - Fever or chills during or after administration. - Headache or mild dizziness. - Nausea or abdominal discomfort. - Arthralgia or joint pain. - Transient increase in liver enzymes.

Serious or Rare Side Effects: - Anaphylactic or severe allergic reactions. - Development of neutralizing antibodies (inhibitors) against factor IX. - Thrombotic events such as deep vein thrombosis. - Viral transmission risk from biologic product. - Severe hemolysis or renal impairment. - Unexpected bleeding despite therapy.

Before using Octanine, certain precautions should be observed. - Inhibitor monitoring: regularly assess for development of anti‑factor IX antibodies. - Infection screening: ensure donor-derived product is free from viral contaminants. - Hypersensitivity: avoid in patients with known allergy to factor IX or excipients. - Concomitant anticoagulants: adjust therapy to prevent over‑ or under‑coagulation. - Pediatric and elderly patients: monitor dosing and response closely. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octanine can interact with other agents affecting coagulation.

Major Interactions (Avoid): - Concurrent use of other pro‑coagulant factor concentrates may increase thrombosis risk. - Simultaneous administration of high‑dose anticoagulants (e.g., warfarin) can negate therapeutic effect.

Moderate Interactions (Monitor Closely): - Use with antifibrinolytic agents (e.g., tranexamic acid) requires monitoring for excessive clot formation. - Combination with immunosuppressive drugs may influence inhibitor development. - Co‑administration with heparin may require dose adjustments and coagulation monitoring.